Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

HARROW, INC. Major Shareholding Notification 2012

Apr 28, 2012

31774_mrq_2012-04-30_e5fd5ef0-6e6f-4ae2-af3f-0b21ecfbd087.zip

Major Shareholding Notification

Open in viewer

Opens in your device viewer

SC 13G 1 f13g042712_sc13g.htm SCHEDULE 13G html PUBLIC "-//IETF//DTD HTML//EN" SCHEDULE 13G

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

IMPRIMIS PHARMACEUTICALS, INC.

(Name of Issuer)

Common Stock, $0.001 par value

(Title of Class of Securities)

45323A 102

(CUSIP Number)

February 28, 2012

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

. Rule 13d-1(b)

. Rule 13d-1(c)

X . Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 45323A 102
1. Names of Reporting Persons. Alexej Ladonnikov
2. Check the Appropriate Box if a Member of a Group (see instructions) (a) . (b) .
3. SEC Use Only
4. Citizenship or Place of Organization U.S.A
Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power 1,984,156
6. Shared Voting Power 0
7. Sole Dispositive Power 1,984,156
8. Shared Dispositive Power 0
9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,984,156
10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions) .
11. Percent of Class Represented by Amount in Row (9) 8.94% 1
12. Type of Reporting Person (see instructions) IN

ITEM 1.

(a) Name of Issuer:

Imprimis Pharmaceuticals, Inc.

(b) Address of Issuer's Principal Executive Offices:

437 S. Highway 101, Suite 209

Solana Beach, CA 92075


1 The percentage was calculated based upon 22,190,526 shares of Common Stock outstanding as of April 27, 2012.

2

ITEM 2.

(a) Name of Person Filing:

Alexej Ladonnikov

(b) Address of Principal Business Office, or if None, Residence:

13388 Surrey Lane

Saratoga, CA 95070

(c) Citizenship:

U.S.A.

(d) Title of Class of Securities:

Common Stock, par value $0.001

(e) CUSIP Number:

45323A 102

ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

Not applicable.

ITEM 4. OWNERSHIP.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned:

1,984,156

(b) Percent of class:

8.94%

(c) Number of shares as to which such person has:

(i) Sole power to vote or to direct the vote

1,984,156

(ii) Shared power to vote or to direct the vote

0

(iii) Sole power to dispose or to direct the disposition of

1,984,156

(iv) Shared power to dispose or to direct the disposition of

0

3

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

Not Applicable.

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

Not Applicable.

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.

Not Applicable.

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

Not Applicable.

ITEM 9. NOTICE OF DISSOLUTION OF GROUP.

Not Applicable.

ITEM 10. CERTIFICATIONS.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: April 27, 2012 ALEXEJ LADONNIKOV /s/ Alexej Ladonnikov By: Alexej Ladonnikov An individual

4

EDGAR Validation Code: 55F732E8